B of A Securities analyst Michael Ryskin downgrades Singular Genomics Sys (NASDAQ:OMIC) from Buy to Underperform and announces $3 price target.
TC BioPharm Announces Successful Completion Of Safety Cohort And Gives Data Safety Monitoring Board Results; No Significant Safety Concerns Observed In Safety Cohort
No Significant Safety Concerns Observed in Safety CohortManagement expects to expand ACHIEVE trial in Q1EDINBURGH, Scotland, Nov. 14, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company")
